DOCSLIB.ORG

Uhm Phd 6916652 R.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

This dissertation has been microfilmed exactly as received 69-16,652 GHOURI, Mohammad Sarfraz Khan, 1940·­ CHEMISTRY AND PHARMACOLOGY OF ADRENERGIC BLOCKING AGENTS. University of Hawaii, Ph.D., 1969 Pharmacology University Microfilms, Inc., Ann Arbor, Michigan CHEMISTRY AND PHARMACOLOGY OF ADRENERGIC BLOCKING AGENTS A DISSERTATION SUBMITTED TO THE GRADUATE DIVISION OF THE UNIVERSITY OF HAWAII IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACOLOGY JANUARY 1969 By 1-- r ((I. f f LO 11 Mohammad S~ K!' Ghour1. Dissertation Committee: Thomas J. Haley, Chairman Louis J. Casarett Daniel D. Palmer Lawrence H. Piette Martin D. Rayner ACKNOWLEDGEMENT The only wisdom I have displayed in this study was in the choice of my professors who tmpressed upon me the importance of human relations in molding a career. It is with deep sense of gratitude that I wish to express my appreciation to the members of the Dissertation Committee for their guidance and valuable suggestions. I am deeply indebted to the East-West Center for financial support and for providing a unique opportunity to participate in an international program for Cultural and Technical Interchange. Appreciation are expressed to many others in the Department of Pharmacology. I am particularly grateful to Mrs. Kathryn Yamashiro for her skill in converting a palimpsest to a legible typescript, and to Mr. Nathan Komesu for his cooperation. My final thanks are due to the following companies for the generous supply of the drugs used in this investigation~ Ciba Pharmaceuticals; Merck, Sharp and Dohme; Eli Lilly and Company; U. S. Vitamins and Pharmaceutical Corporation; Burroughs Wellcome and Company; Warner­ Lambert, Wyeth Laboratories Inc.; McNeil Laboratories; Sterting­ Winthrop, and Smith, Kline and French Laboratories. CHEMISTRY AND PHARMACOLOGY OF ADRENERGIC BLOCKING AGENTS A dissertation submitted to the Graduate Division of the University of Hawaii in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ABSTRAGr Studies on the isolated rabbit ileum indicate that this preparation reacts differently to stimulation or blockade of the alpha or beta adrenergic receptors, and thus may be used as a differentiation test object to ascertain the type of receptor involved in the response obtained. This preparation can also be used to differentiate between the drugs that produce their effects by releasing norepinephrine. This tissue is also suitable for demonstrating nonspecific musculotropic actions of drugs. The hormone treated rabbit uterus had alpha and beta adrenergic receptors, and stimulation of the former results in contraction and the latter in relaxation. During the course of study on sympathomimetic drugs, a peculiar observation was made that cyclopentamine effectively blocked isoproterenol-induced inhibition on the ileal and the uterine preparations. Cyclopentamine-induced beta receptor blockade was not to be expected since the structure of this drug had none of the characteristic features of the known beta receptor blocking agents. This finding not only points out that the current hypotheses regarding the structure-activity relationships of adrenergic drugs are inadequate but also makes it imperative that any further speculations on the ~ structure-activity relationships in adrenergic drugs and thereby on the chemical nature of adrenergic receptors ~t consider the dynamic nature of the structures of drug, receptor and the receptor environment. MOreover, it may be stressed that the drug molecule as a whole determines the nature of the biological activity of the drug, and the receptor environment should not be considered irrelevant in any receptor-dependent pharmacological activity. It seems that cyclopentamine has the ability to produce beta receptor blockade by directly acting at beta adrenergic receptor as well as by causing a change in the degree of influence of the receptor environment on the beta receptor activity. Cyclopentamine also provides an indirect evidence that the beta receptor activity is susceptible to the dynamic changes occurring in the vicinity of the receptor. The beta receptor blocking action of cyclopentamine, therefore, suggests a new approach to adrenergic mechanisms, and provides a new basic structure for the development of beta receptor blocking drugs. The presence of an isopropyl group on the amino nitrogen and the catechol hydroxyl groups were found to increase specificity with resultant increase in the intrinsic activity at beta receptor. But these groups do not seem to define absolute structural requirements for activity at beta receptors. However, the presence of the beta hydroxyl group in beta receptor agonists is essential. The only essential requirement for intrinsic activity at alpha adrenergic receptor is the presence of the ethylamine side chain. Substitution in the ethylamine moiety invariably decreases alpha receptor stimulating activity. With large substituent groups alpha v receptor blocking property is obtained. It appears that an aromatic ring is required for alpha adrenergic receptor blocking action since no aliphatic amine was found to have alpha receptor blocking activity. Substitution in the ethyl moiety decreases affinity for alpha receptor, but produces sympathomimetic amines that act by releasing norepinephrine. TABLE OF CONTENTS PAGE ACi<Ncm.EDGEMENT . • · · • · · · · · · · · · ii ABS'rRAGr . · · · · · · · ··· · iii LIST OF TABLES • . · • . · · · · · • ·· · · · · · viii LIST OF ILLUS'rRATIONS . · · · · · · · · · · · · · x CHAPTER I. INTRODUGrION ·· · · · · · · · · · · 1 A. Review of Literature • · · ··· 1 l. Preparations with alpha receptors • 6 2. Preparations with beta receptors · · 8 3. Structure-Activity relationships of alpha receptor blocking agents · · · · · · · · · · · · 9 (a) Ergot alkaloids 10 (b) Yohimbine and related alkaloids 14 (c) Benzodioxans · · 14 (d) Phenoxyethylamines· · · · · 17 (e) Beta-haloalkylamines · · · · 18 (f) Phenoxybenzamines ·· · · 31 (g) Dibenzazepines · · 40 (h) Pyrrolidines · · 41 (i) Piperazines · · · 43 (j) Tetrazoles · · ·· · · • 49 (k) Imidazolines· · · ···· · · · · 52 4. Structure-Activity relationships of beta-receptor blocking agents • 56 5. Stereochemical aspects • ·· · 72 6. Effects of adrenergic receptors· · · · blocking agents on the nervous system · • 75 7. Antiarrhythmic properties· ·· ·· · ·• 79 8. Metabolic effects of adrenergic · ·· receptors blocking agents 85 B. Statement of the Problem · • · • · · 93 C. Objectives of the Studies · · ·· 97 vii TABLE OF CmlTENTS (Cont'd) PAGE CHAPTER II. METHODS AND MATERIALS •• . · .. · ... 96 1. Introduction ••••••••••••• 96 2. Selection of tissue preparations ••••• 96 (a) Isolated ileal preparation 99 (b) Isolated uterine preparation •• 99 3. Experimental details 101 (a) Determination of alpha receptor stimulating property •••••• 103 (b) Determination of alpha receptor blocking property •••••• 104 (c) Determination of beta receptor stimulating property ••••• 105 (d) Determination of beta receptor blocking property ••••••••• 105 4. Analysis of results •• 106 5. Drugs and solutions •• 111 CHAPTER III. RESULTS, DISCUSSIONS AND CONCLUSIONS 115 1. Basis for interpretation and integration data . • · 115 2. Alkylethylamine series · ·· · · 118 3. Phenylalkylamine series · · . · · ·· · 123 4. Phenylalkanolamine series· · · .. · 129 5. Heterocyclic compounds • · · · · 132 6. Congeners of dichloroisoproterenol • · · • 137 CHAPTER IV. SUMMARY . ... .. 163 APPENDIX . .. .. .. 168 BIBLIOGRAPHY .. .. .... ·. 173 LIST OF TABLES TABLE PAGE I COMPARISON OF ACTIONS OF NOREPINEPHRmE AND ISOPROTERENOL AND THE TYPES OF ADRENERGIC RECEPTORS IN VARIOUS TISSUES ••••••••••• 3 II ADRENERGIC BLOCKING DRUGS ••• 11 III STRUCTURE-ACTIVITY RELATIONSHIPS m PHENYLALKANOLAMINES ••• ••• 57 IV STRUCTURE-ACTIVITY RELATIONSHIPS IN SULFONAMIDO SUBSTITUTED PHENYLALKANOLAMINES . ... 65 V COMPARISON OF POTENCY OF ALPHA-RECEPTOR BLOCKING AGENTS AND THEIR ISOMERS •••• . .. 74 VI COMPARISON OF ALPHA-RECEPI:OR STIMULATING PROPERTIES •••••••••••• . 119 VII POTENCY COMPARISON OF ALPHA-RECEPTOR STD1ULANTS••••••••••• 120 VIII STRUCTURE-ACTIVITY RELATIONSHIPS m ALKYLETHYLAMmE SERIES ••••••• 122 IX COMPARISON OF ALPHA-RECEPI:OR BLOCKING PROPERTIES ON ISOLATED RABBIT ILEUM •• •••••••••••••• 124 X COMPARISON OF ALPHA RECEPTOR BLOCKING PROPERTIES ON ISOLATED RABBIT UTERUS •••••••••••••••• 125 XI POTENCY COMPARISON OF ALPHA-RECEPTOR BLOCKING AGEN'TS •••••••••••• ••••• 126 XII STRUCTURE-ACTIVITY RELATIONSHIPS m PHENYLALKYLAMINE SERIES •••• 127 XIII STRUCTURE-ACTIVITY RELATIONSHIPS IN PHENYLALKANOLAMINE SERIES •••• •• . .. 131 XIV COMPARISON OF SLOPE RATIOS AND SLOPE FACTORS FOR. ALPHA-RECEPTOR STIMULANTS . .. 138 xv COMPARISON OF SLOPE RATIOS AND SLOPE FACTORS FOR ALPHA-RECEPTOR BLOCKING AGENTS ON ISOLATED ILEUM ••••• 139 ix LIST OF '!ABLES (Cont'd) '!ABLE PAGE XVI COMPARISON OF SLOPE RATIOS AND SLOPE FACTORS FOR ALPHA-RECEPTOR BLOCKING AGENTS ON ISOLATED UTERUS ••••• . .. 140 XVII COMPARISON OF BETA RECEPTOR BLOCKING PROPERTIES •••• · . .. 143 XVIII POTENCY COMPARISON OF BETA RECEPTOR BLOCKING AGENTS •• · ... ..... .. 144 XIX COMPARISON OF BETA RECEPTOR STIMULATING PROPERTIES 148 xx POTENCY COMPARISON OF BETA RECEPTOR STIMULANTS ••• ·... ... ... 149 XXI STRUCTURE-ACTIVITY RELATIONSHIPS OF CONGENERS OF DICHLOkOISOPROTERENOL 151 XXII COMPARISON OF SLOPE RATIOS AND SLOPE FACTORS FOR BETA RECEPTOR STIMULANTS 155 XXIII COMPARISON OF SLOPE RATIOS AND SLOPE FACTORS FOR BETA RECEPTOR BLOCKING AGENTS . 156 LIST OF ILLUSTRATIONS FIGURE
Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
  • House Bill No. 2191

    House Bill No. 2191

    SECOND REGULAR SESSION HOUSE BILL NO. 2191 99TH GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE QUADE. 5582H.01I D. ADAM CRUMBLISS, Chief Clerk AN ACT To repeal section 579.060, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with penalty provisions. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Section 579.060, RSMo, is repealed and one new section enacted in lieu 2 thereof, to be known as section 579.060, to read as follows: 579.060. 1. A person commits the offense of unlawful sale, distribution, or purchase of 2 over-the-counter methamphetamine precursor drugs if he or she knowingly: 3 (1) Sells, distributes, dispenses, or otherwise provides any number of packages of any 4 drug product containing detectable amounts of ephedrine, levomethamphetamine, 5 phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any of their salts, optical 6 isomers, or salts of optical isomers, in a total amount greater than nine grams to the same 7 individual within a thirty-day period, unless the amount is dispensed, sold, or distributed 8 pursuant to a valid prescription; or 9 (2) Purchases, receives, or otherwise acquires within a thirty-day period any number of 10 packages of any drug product containing any detectable amount of ephedrine, 11 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any 12 of their salts or optical isomers, or salts of optical isomers in a total amount greater than nine 13 grams, without regard to the number of transactions, unless the amount is purchased, received, 14 or acquired pursuant to a valid prescription; or 15 (3) Purchases, receives, or otherwise acquires within a twenty-four-hour period any 16 number of packages of any drug product containing any detectable amount of ephedrine, 17 levomethamphetamine, phenylpropanolamine, propylhexedrine, or pseudoephedrine, or any EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
  • Effect of Sympathomimetic and Allied Amines on Temperature and Oxygen Consumption in Chickens by D

    Effect of Sympathomimetic and Allied Amines on Temperature and Oxygen Consumption in Chickens by D

    Br. J. Pharmac. Chemother. (1967), 31, 290-312. EFFECT OF SYMPATHOMIMETIC AND ALLIED AMINES ON TEMPERATURE AND OXYGEN CONSUMPTION IN CHICKENS BY D. J. ALLEN AND E. MARLEY From the Institute of Psychiatry, Maudsley Hospital, Denmark Hill, London (Received June 12, 1967) The sympathomimetic and allied amines can be divided into two main groups according to their chemical structure and to their effects in young chickens (Key & Marley, 1962; Dewhurst & Marley, 1965a, b). These groups are similar to those into which the amines are divided for their effects on smooth muscle (Fleckenstein & Burn, 1953; Burn & Rand, 1958; Maxwell, Povalski & Plummer, 1959; Vane, 1960; Marley, 1962; Trendelenburg, 1963) and this division clearly implies a fundamental difference in mode of action. In young chickens, catecholamines evoked sleep, whereas amphetamine-like amines and some tryptamines had the opposite effect and produced arousal (Key & Marley, 1962; Dewhurst & Marley, 1965a, b). The present experiments were made to determine the effects of these amines on temperature and oxygen consumption. Our results, a brief account of which was given to the Physiological Society (Allen & Marley, 1966), agree with those of Feldberg & Myers (1963, 1964a, 1965) who found that adrenaline and noradrenaline injected intraventricularly in cats lowered body temperature, whereas 5-hydroxytryptamine raised it. METHODS Animals Rhode Island Red pullets, 1-23 days old and weighing 30 to 150 g, and adult fowls of 1 to 2 kg were used, all from the same hatchery. For the first week after hatching they were kept in a cage thermostatically maintained at 33 to 340 C and for the subsequent 2 weeks at 29 to 310 C.
  • Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental

    Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental

    A RQUIVOS B RASILEIROS DE ORIGINAL ARTICLE Ophthalmic adverse effects of nasal decongestants on an experimental rat model Efeitos oftálmicos adversos de descongestionantes nasais em modelo experimental com ratos Ayse Ipek Akyuz Unsal1, Yesim Basal2, Serap Birincioglu3, Tolga Kocaturk1, Harun Cakmak1, Alparslan Unsal4, Gizem Cakiroz5, Nüket Eliyatkın6, Ozden Yukselen7, Buket Demirci5 1. Department of Ophthalmology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 2. Department of Otorhinolaringology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 3. Department of Pathology, Veterinary Faculty, Adnan Menderes University, Aydin, Turkey. 4. Department of Radiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 5. Department of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 6. Department of Medical Pathology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 7. Department of Pathology, Aydin State Hospital, Aydin, Turkey. ABSTRACT | Purpose: To investigate the potential effects of cause ophthalmic problems such as dry eyes, corneal edema, chronic exposure to a nasal decongestant and its excipients cataracts, retinal nerve fiber layer, and vascular damage in on ocular tissues using an experimental rat model. Methods: rats. Although these results were obtained from experimental Sixty adult male Wistar rats were randomized into six groups. animals, ophthalmologists should keep in mind the potential The first two groups were control (serum physiologic) and ophthalmic adverse effects of this medicine and/or its excipients Otrivine® groups. The remaining four groups received the and exercise caution with drugs containing xylometazoline, Otrivine excipients xylometazoline, benzalkonium chloride, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol, and ethylene diamine tetra acetic acid. Medications sorbitol for patients with underlying ocular problems.
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology

    The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology

    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • Part 1. Synthesis of N-15 Labeled (R)-Deuterioglycine

    Part 1. Synthesis of N-15 Labeled (R)-Deuterioglycine

    PART 1. SYNTHESIS OF N-15 LABELED (R)-DEUTERIOGLYCINE PART 2. SYNTHESES OF CARBON-LINKED ANALOGS OF RETINOID GLYCOSIDE CONJUGATES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Joel R. Walker * * * * * The Ohio State Univeristy 2003 Dissertation Committee: Approved by Robert W. Curley, Jr., Ph.D., Adviser Werner Tjarks, Ph.D. ________________________ Adviser Karl A. Werbovetz, Ph.D. College of Pharmacy ABSTRACT (R)-Glycine-d-15N has been used to permit assignments of the prochiral α-protons of glycine residues in the FK-506 binding protein. A key and low yielding step in the synthetic route to (R)-glycine-d-15N occurred in the ruthenium tetraoxide-mediated degradation of N-t-BOC-p-methoxybenzyl amine to the N-t-BOC-glycine after both 2H and 15N are incorporated. In order to improve this step, investigation of the oxidation reaction conditions along with various aromatic ring carboxylate precursors were undertaken. It was found that using ruthenium chloride, periodic acid as the stoichiometric re-oxidant, and N-(p-methoxyphenylmethylamine)-2,2,2-trichloroethyl carbamate were the optimal conditions and substrate. This improvement was paramount for the applicability of this route for large scale production of labeled glycine that could be used in other biological applications. The retinoic acid analog N-(4-hydroxyphenyl)retinamide (4-HPR) is an effective chemopreventative and chemotherapeutic for numerous types of cancer. In vivo, 4-HPR is metabolized to 4-HPR-O-glucuronide (4-HPROG), which has been shown to be more effective than the parent molecule in rat mammary tumor models.
  • United States Patent (19) 11 4,395,569 Lewis Et Al

    United States Patent (19) 11 4,395,569 Lewis Et Al

    United States Patent (19) 11 4,395,569 Lewis et al. (45) "Jul. 26, 1983 (54) METHOD OF PREPARNG SULFONCACD 58) Field of Search ................... 560/87, 88, 193, 196, SALTS OF ACYLOXYALKYLAMINES AND 560/220, 221, 222, 127, 38, 49, 155, 169, 171, POLYMERS AND COMPOUNDS 74, 80, 153, 154; 54.6/321 THEREFROM (56) References Cited (75) Inventors: Sheldon N. Lewis, Willow Grove; U.S. PATENT DOCUMENTS Jerome F. Levy, Dresher, both of Pa. 2,628,249 2/1953 Bruno . 2,871,258 1/1959 Hidalgo et al. 73) Assignee: Rohm and Haas Company, 3,211,781 10/1965 Taub et al. Philadelphia, Pa. 3,256,318 7/1966 Brotherton et al. 3,459,786 8/1969 Brotherton et al. * Notice: The portion of the term of this patent 3,468,934 9/1969 Emmons et al. subsequent to Mar. 18, 1997, has been 3,729,416 4/1973 Bruning et al. disclaimed. 4,194,052 3/1980 Lewis et al. ........................ 560/222 FOREIGN PATENT DOCUMENTS 21 Appl. No.: 104,256 1351368 2/1964 France . 22 Filed: Dec. 17, 1979 1507036 12/1967 France . Primary Examiner-Natalie Trousof Assistant Examiner-L. Hendriksen Related U.S. Application Data Attorney, Agent, or Firm-Terence P. Strobaugh; (60) Division of Ser. No. 821,068, May 1, 1969, Pat. No. George W. F. Simmons 4,194,052, which is a continuation-in-part of Ser. No. 740,480, Jun. 27, 1968, Pat. No. 4,176,232. 57 ABSTRACT A sulfonic acid salt of an acyloxyalkylamine is prepared (51) Int, C. ..................... C07C 67/08; C07C 101/00 by reaction of an organic acid or amino-acid with a (52) U.S.
  • Emerging New Types of Absorbents for Postcombustion Carbon Capture

    Emerging New Types of Absorbents for Postcombustion Carbon Capture

    Faculty Scholarship 2017 Emerging New Types of Absorbents for Postcombustion Carbon Capture Quan Zhuang Natural Resources Canada Bruce Clements CanmetENERGY Bingyun Li West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications Part of the Engineering Commons Digital Commons Citation Zhuang, Quan; Clements, Bruce; and Li, Bingyun, "Emerging New Types of Absorbents for Postcombustion Carbon Capture" (2017). Faculty Scholarship. 1245. https://researchrepository.wvu.edu/faculty_publications/1245 This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted for inclusion in Faculty Scholarship by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. ProvisionalChapter chapter 4 Emerging New TypesTypes ofof AbsorbentsAbsorbents for for Postcombustion Carbon Capture Postcombustion Carbon Capture Quan Zhuang, Bruce Clements and Bingyun Li Quan Zhuang, Bruce Clements and Bingyun Li Additional information is available at the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/65739 Abstract Carbon capture is the most probable technology in combating anthropogenic increase of CO2 in the atmosphere. Works on developing emerging absorbents for improving carbon capture performance and reducing process energy consumption are actively going on. The most worked‐on emerging absorbents, including liquid‐liquid biphasic, liquid‐solid biphasic, enzymatic, and encapsulated absorbents, already show encouraging results in improved energy efficiency, enhanced CO2 absorption kinetics, increased cyclic CO2 loading, or reduced regeneration temperature. In this chapter, the latest research and development progress of these emerging absorbents are reviewed along with the future directions in moving these technologies to higher‐technology readiness levels.
  • The 2014 Prohibited List International Standard

    The 2014 Prohibited List International Standard

    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
  • View and Critique My Work

    View and Critique My Work

    UNIVERSITY OF CINCINNATI Date:___________________ I, _________________________________________________________, hereby submit this work as part of the requirements for the degree of: in: It is entitled: This work and its defense approved by: Chair: _______________________________ _______________________________ _______________________________ _______________________________ _______________________________ Biodegradation and Environmental Fate of Nonylphenol A thesis submitted to the Division of Graduate Studies and Research of the University of Cincinnati in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Chemical Engineering from the Department of Chemical and Materials Engineering of the College of Engineering August 2004 By Marcus A. Bertin B.S., (ChemE), University of Cincinnati Cincinnati, Ohio, 2001 Under the Advisement of Dr. Panagiotis G. Smirniotis Abstract Concern for the fate of nonylphenol (NP) has increased in recent years due to reports that it is an endocrine disrupting compound and that it is persistent in the environment. The biodegradation of NP was examined through the use of microcosms and respirometers. NP biodegradation was examined under aerobic, nitrate reducing, sulfate reducing, and methanogenic conditions. Through the use of gas chromatography- mass spectroscopy, the technical mixture of NP was differentiated into 23 isomers. Since no standards are available, a novel technique was used to quantify the isomers of NP. Under aerobic conditions, biodegradation rates for some isomers differed significantly, indicating that some isomers are more resistant to biodegradation. Comparisons between known isomer structures and biodegradation rates show that correlations exist between the branching of the alkyl chain and biodegradability. Under anoxic conditions, NP degradation using cultures obtained from the anaerobic digester of a local wastewater treatment plant did not occur.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.